Royal Bank Of Canada Alaunos Therapeutics, Inc. Transaction History

Royal Bank Of Canada

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.04 - $0.13 $2,964 - $9,634	-74,109 Reduced 98.1%	1,434 $0
Q3 2023 Nov 14, 2023	BUY	$0.12 - $0.5 $8,913 - $37,137	74,275 Added 5857.65%	75,543 $9,000
Q2 2023 Aug 14, 2023	BUY	$0.43 - $0.65 $250 - $378	583 Added 85.11%	1,268 $0
Q1 2023 May 15, 2023	BUY	$0.46 - $0.81 $173 - $306	378 Added 123.13%	685 $0
Q4 2022 Feb 14, 2023	SELL	$0.5 - $261.0 $8,846 - $4.62 Million	-17,692 Reduced 98.29%	307 $0
Q3 2022 Nov 14, 2022	BUY	$1.04 - $322.5 $9,825 - $3.05 Million	9,448 Added 110.49%	17,999 $31,000
Q2 2022 Aug 15, 2022	SELL	$0.41 - $1.24 $5,140 - $15,548	-12,539 Reduced 59.45%	8,551 $10,000
Q1 2022 May 16, 2022	SELL	$0.62 - $1.17 $18,564 - $35,032	-29,942 Reduced 58.67%	21,090 $13,000
Q4 2021 Feb 14, 2022	BUY	$1.09 - $1.89 $26,911 - $46,662	24,689 Added 93.72%	51,032 $56,000
Q3 2021 Nov 15, 2021	BUY	$1.44 - $2.73 $5,441 - $10,316	3,779 Added 16.75%	26,343 $48,000
Q2 2021 Aug 16, 2021	BUY	$2.63 - $3.67 $59,343 - $82,809	22,564 New	22,564 $60,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $458M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.